269 related articles for article (PubMed ID: 36999711)
1. Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's Disease.
Bezard E; Gray D; Kozak R; Leoni M; Combs C; Duvvuri S
CNS Neurol Disord Drug Targets; 2024; 23(4):476-487. PubMed ID: 36999711
[TBL] [Abstract][Full Text] [Related]
2. Dopamine agonists in Parkinson's disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment.
Isaacson SH; Hauser RA; Pahwa R; Gray D; Duvvuri S
Clin Park Relat Disord; 2023; 9():100212. PubMed ID: 37497384
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.
Fariello RG
Drugs; 1998; 55 Suppl 1():10-6. PubMed ID: 9483165
[TBL] [Abstract][Full Text] [Related]
4. Advances in the Therapeutic Use of Non-Ergot Dopamine Agonists in the Treatment of Motor and Non-Motor Symptoms of Parkinson's Disease.
Jing XZ; Yang HJ; Taximaimaiti R; Wang XP
Curr Neuropharmacol; 2023; 21(5):1224-1240. PubMed ID: 36111769
[TBL] [Abstract][Full Text] [Related]
5. Alternatives to levodopa in the initial treatment of early Parkinson's disease.
Lees A
Drugs Aging; 2005; 22(9):731-40. PubMed ID: 16156677
[TBL] [Abstract][Full Text] [Related]
6. D
Mailman RB; Yang Y; Huang X
Eur J Pharmacol; 2021 Feb; 892():173760. PubMed ID: 33279520
[TBL] [Abstract][Full Text] [Related]
7. Dopaminergic agonists in the treatment of Parkinson's disease: a review.
Piccoli F; Riuggeri RM
J Neural Transm Suppl; 1995; 45():187-95. PubMed ID: 8748625
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson's Disease following Oral Administration.
Papapetropoulos S; Liu W; Duvvuri S; Thayer K; Gray DL
Neurodegener Dis; 2018; 18(5-6):262-269. PubMed ID: 30453303
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N;
Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739
[TBL] [Abstract][Full Text] [Related]
10. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
[TBL] [Abstract][Full Text] [Related]
11. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease.
Jenner P
Curr Opin Neurol; 2003 Dec; 16 Suppl 1():S3-7. PubMed ID: 15180131
[TBL] [Abstract][Full Text] [Related]
12. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
[TBL] [Abstract][Full Text] [Related]
13. Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.
Bennett JP; Piercey MF
J Neurol Sci; 1999 Feb; 163(1):25-31. PubMed ID: 10223406
[TBL] [Abstract][Full Text] [Related]
14. The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson's Disease: A Feasibility Study.
Huang X; Lewis MM; Van Scoy LJ; De Jesus S; Eslinger PJ; Arnold AC; Miller AJ; Fernandez-Mendoza J; Snyder B; Harrington W; Kong L; Wang X; Sun D; Delnomdedieu M; Duvvuri S; Mahoney SE; Gray DL; Mailman RB
J Parkinsons Dis; 2020; 10(4):1515-1527. PubMed ID: 32986682
[TBL] [Abstract][Full Text] [Related]
15. Endogenous dopaminergic tone and dopamine agonist action.
Treseder SA; Smith LA; Jenner P
Mov Disord; 2000 Sep; 15(5):804-12. PubMed ID: 11009183
[TBL] [Abstract][Full Text] [Related]
16. Pergolide in the treatment of patients with early and advanced Parkinson's disease.
Bonuccelli U; Colzi A; Del Dotto P
Clin Neuropharmacol; 2002; 25(1):1-10. PubMed ID: 11852289
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
[TBL] [Abstract][Full Text] [Related]
18. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
Dooley M; Markham A
Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
[TBL] [Abstract][Full Text] [Related]
19. Dopaminergic substitution in Parkinson's disease.
Müller T
Expert Opin Pharmacother; 2002 Oct; 3(10):1393-403. PubMed ID: 12387685
[TBL] [Abstract][Full Text] [Related]
20. The role of dopamine agonists in early Parkinson's disease.
Watts RL
Neurology; 1997 Jul; 49(1 Suppl 1):S34-48. PubMed ID: 9222273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
